50 results about "Lung Disorder" patented technology

Provided are compositions and methods for treating lung or respiratory disorders or conditions characterized by airflow obstruction or limitation, or a symptom thereof (e.g., asthma, rhinitis, allergic rhinitis, and chronic obstructive pulmonary disease (COPD) and COPD-associated conditions (e.g., bronchitis, emphysema, asthma), emphysema, pneumonia, bronchitis, influenza, SARS, tuberculosis, and whooping cough (pertussis), and the like) in a subject in need thereof by administering a therapeutic composition comprising at least one electrokinetically altered fluid (gas-enriched (e.g., oxygen-enriched) electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures as disclosed herein. In certain aspects, the methods comprise regulating intracellular signal transduction by modulation of at least one of cellular membranes, membrane potential, membrane proteins (e.g., membrane receptors, (e.g., to G protein coupled receptors, and intercellular junctions)). Additional aspects include therapeutic compositions, and combination treatment methods comprising administration of electrokinetically generated fluid in combination with at least one additional therapeutic agent.

Methods and systems are disclosed for the detecting of whether a subject has a lung disorder such as asthma, tuberculosis or lung cancer. Monitoring the subject's health and prognosis is also disclosed.

Provided are compositions and methods for treating lung or respiratory disorders or conditions characterized by airflow obstruction or limitation, or a symptom thereof (e.g., asthma, rhinitis, allergic rhinitis, and chronic obstructive pulmonary disease (COPD) and COPD-associated conditions (e.g., bronchitis, emphysema, asthma), emphysema, pneumonia, bronchitis, influenza, SARS, tuberculosis, and whooping cough (pertussis), and the like) in a subject in need thereof by administering a therapeutic composition comprising at least one electrokinetically altered fluid (gas-enriched (e.g., oxygen-enriched) electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures as disclosed herein. In certain aspects, the methods comprise regulating intracellular signal transduction by modulation of at least one of cellular membranes, membrane potential and / or conductance, membrane proteins (e.g., membrane receptors, (e.g., to G protein coupled receptors, and intercellular junctions)). Additional aspects include therapeutic compositions, and combination therapies comprising administration of the electrokinetically generated fluids with at least one additional therapeutic agent.

Described herein are multifactorial methods for detecting, diagnosing or aiding in the diagnosis of lung disorders or disease, e.g., lung cancer. The methods disclosed utilize multiple diagnostic paradigms, for example, to improve diagnostic sensitivity, specificity, negative predictive value and / or positive predictive value over each of the paradigms alone. For example, a clinicogenomic model is disclosed for lung cancer diagnosis which combines clinical factors and gene expression, particularly a sensitive and specific gene expression biomarker.

The present invention relates to pharmaceutical compositions and methods for the prevention and / or treatment of lung diseases or disorders including the bronchial tree, in an animal or human, such as chronic obstructive pulmonary disease (COPD), and diseases related to or optionally associated with COPD-like lung disorders caused by ventilation-perfusion mismatches preferably in context with chronic bronchitis. The treatment includes administration of pharmaceutical compositions comprising vasoactive intestinal peptide (VIP), pituitary adenylate cyclase-activating polypeptide (PACAP), and biologically active analogues thereof, which comprise highly conservative sequence tracks.

Provided are compositions and methods for treating lung or respiratory disorders or conditions characterized by airflow obstruction or limitation, or symptoms thereof (e g, asthma, rhinitis, allergic rhinitis, and chronic obstructive pulmonary disease (CaPO) and CaPO-associated conditions (e g, bronchitis, emphysema, asthma), emphysema, pneumonia, bronchitis, in-fluenza, SARS, tuberculosis, and whooping cough (pertussis), and the like) comprising administering a therapeutic composition comprising at least one electrokinetically altered fluid comprising an ionic aqueous solution of charge-stabilized oxygen containing nanostructures as disclosed herein, or comprising administering a nonelectrokinetic superoxygenated aqueous solution The methods preferably comprise regulating intracellular signal transduction by modulation of at least one of cellular membranes, membrane potential, membrane proteins (e g, membrane receptors, (e g, G protein-coupled receptors, and intercellular junctions)) Additional aspects include therapeutic compositions, and combination treatment methods comprising administration of electrokinetically generated fluid in combination with at least one additional therapeutic agent (e g, albuterol, etc).

The present invention provides methods for treating inflammatory diseases, or conditions associated with, or resulting in part from, elevated levels of IL-33 and IL-4, in particular inflammatory lung disorders. The methods of the present invention comprise administering to a subject in need thereof one or more therapeutically effective doses of an IL-33 antagonist alone or in combination with one or more therapeutically effective doses of an IL-4R antagonist. In certain embodiments, the methods of the present invention include use of the antagonists to treat any inflammatory disease or condition mediated in part by enhanced IL-33-mediated signaling and IL-4-mediated signaling.

Formulations of human amniotic fluid and methods of use thereof for treatment of lung disorders, and / or injuries have been developed. The formulations are suitable for topical delivery to the lung for treatment of lung disorders including chronic obstructive pulmonary disorders (COPD), asthma, emphysema, bronchiectasis, chronic bronchitis, interstitial lung disease, alpha-1 antitrypsin emphysema, as well as for treatment of acute lung injuries. Methods including administering specifically formulated, diluted sterile de-cellularized human amniotic fluids topically to the lungs, preferably as aerosol droplets, are described. In particular, the methods involving administration of the amniotic fluid formulation in the form of aerosol droplets with size between about 1.5 μm to about 5 μm, preferably from about 2.5 μm to about 3.5 μm, inclusive, using apparatus such as high-efficiency vibrating mesh nebulizers, are described. Formulations described can treat, or prevent one or more symptoms of a chronic lung disorder.

The present invention provides methods for diagnosis and prognosis of lung cancer using expression analysis of one or more groups of genes, and a combination of expression analysis from a nasal epithelial cell sample. The methods of the invention provide far less invasive method with a superior detection accuracy for lung cancer when compared to any other currently available method for lung cancer diagnostic or prognosis. The invention also provides methods of diagnosis and prognosis of other lung diseases, such as lung cancer.

Disclosed herein are compositions and methods for treating lung disorders including lung tumors by pulmonary administration of compositions comprising taxane particles such as docetaxel or paclitaxel particles.

The invention features a method for inhibiting or reducing the deleterious effects of tobacco smoking including increased incidence of cancers, cardiovascular diseases, various lung disorders and the oxidative effects. The method includes the incorporation of an effective amount of a compound or a standardized plant extract that is that comprises an inhibitor of antioxidant stress due to the induction of phase 2 enzymes regulated by Nerf2 into tobacco or a tobacco product.

The invention discloses a dust cleaning system based on artificial intelligence. The dust cleaning system comprises a dust suction hood, a dust removal tower and a water supply tank, a primary dust removal mechanism and a secondary dust removal mechanism are sequentially arranged in the dust removal tower from bottom to top, the primary dust removal mechanism is connected with the dust suction hood, and the bottom of the primary dust removal mechanism communicates with the water supply tank through a filtering mechanism; the top of the primary dust removal mechanism is communicated with the bottom of the secondary dust removal mechanism, a spraying mechanism is arranged above the secondary dust removal mechanism, the spraying mechanism is connected with a circulating water pump arranged in the water supply tank through a water inlet pipe, and an exhaust hole is formed in the top of the dust removal tower. The dust cleaning system is used for cleaning dust existing in a factory workshop, the dust is separated and filtered through the primary dust removal mechanism, filtered air enters the secondary dust removal mechanism, the secondary dust removal mechanism is matched with the spraying mechanism to fully absorb and remove residual dust, and then clean air is discharged through the dust removal tower. The harm of dust in production and life can be solved, and lung diseases are avoided.

The cytokine ML-1 is a target for treating airway inflammation. Candidate therapeutic agents for treating airway inflammation can be screened for the ability to bind to an ML-1 protein or polynucleotide, from the ability to decrease functional properties of ML-1, or for the ability to decrease ML-1 gene expression. Pharmaceutical compositions comprising such reagents can be used to treat airway inflammation associated with a variety of lung disorders, such as asthma, chronic obstructive pulmonary disease, emphysema, allergic inflammatory responses, and cystic fibrosis.

The invention discloses a ventilating lung qi capsule and a preparation method thereof. The ventilating lung qi capsule mainly selects and uses dried santal leaves, sophora viciifolia roots, eurya nitida, Kalopanax septemlobus tree leaves, plum flowers, twotooth achyranthes roots, herba houttuyniae, Chinese rose flower roots, floating ferns, tirpitzia ovoidea, olives, photinia fruits, euphorbia humifusa, bamboo leaf pepper, pansies, Amaranthus caudatus leaves, folium ilicis purpurea, parthenocissus henryana, calamine, sedum lineare and the like. An advanced extracting preparation technology is used for producing, and the ventilating lung qi capsule can effectively cure a chronic obstructive pulmonary disease.

The present invention provides methods for treating inflammatory diseases, or conditions associated with, or resulting in part from, elevated levels of IL-33 and IL-4, in particular inflammatory lung disorders. The methods of the present invention comprise administering to a subject in need thereof one or more therapeutically effective doses of an IL-33 antagonist alone or in combination with one or more therapeutically effective doses of an IL-4R antagonist. In certain embodiments, the methods of the present invention include use of the antagonists to treat any inflammatory disease or condition mediated in part by enhanced IL-33-mediated signaling and IL-4-mediated signaling.

Disclosed is a method for the prevention and / or treatment of a chronic obstructive pulmonary disease by administrating a 5-membered cyclic compound represented by the formula below or a pharmaceutically acceptable salt of the compound or a prodrug of the compound or salt: wherein X represents an oxygen or sulfur atom; R1 represents a hydrogen atom, a substituted or unsubstituted alkyl or the like; R2 represents a hydrogen atom, a substituted or unsubstituted alkyl or the like; Y1 represents a single bond, a substituted or unsubstituted alkylene or the like; the wavy line means an (E) or (Z) coordination; R3 represents a hydrogen atom, a substituted or unsubstituted aryl or the like; Y2 represents a substituted or unsubstituted alkylene or an alkenylene; R4 represents a hydrogen atom, a substituted or unsubstituted alkanoyl or the like; and R5 represents a hydrogen atom or a substituted or unsubstituted alkyl.

The present invention relates to the treatment of fibrotic disorders. More particularly, the present invention relates to the use of a neuregulin protein in a method treating, preventing and / or delaying fibrotic skin disorders, fibrotic lung disorders or liver cirrhosis.

The disclosure provides compositions comprising 15-HEPE or derivatives thereof used singly or in combination with other active agents for the treatment and / or prevention of lung diseases and disorders such as asthma.

The combination of nitric oxide generating compounds which are not dependent upon aldehyde dehydrogenase for bioactivation, or are specifically targeted to nNOS or the sarcoplasmic reticulum of cardiac muscle cells, and xanthine oxidase inhibitors are effective in the treatment of heart disease, specifically congestive heart failure and ischemic coronary disease. This treatment is particularly effective in patients who have particularly heavy oxidative burdens, e.g. diabetics, patients with lung disorders, patients with sickle cell anemia and patients of Asian descent.